Brief: Corcept To Resubmit NDA For Relacorilant As Treatment For Cushing's Syndrome Patients

Corcept Therapeutics Incorporated

27/05/2026 13:18

May 27 (Reuters) - Corcept Therapeutics Inc CORT.O:
TO RESUBMIT ITS NEW DRUG APPLICATION FOR RELACORILANT AS A TREATMENT FOR PATIENTS WITH CUSHING’S SYNDROME
FDA EXPECTS PDUFA DATE SIX MONTHS AFTER NDA RESUBMISSION FOR RELACORILANT
Source text: ID:nBw2FWxM2a
Further company coverage: CORT.O

 ((Reutersbriefs@thomsonreuters.com;))